Synageva BioPharma Corp Director Barry D. Quart Sells 1,375 Shares (GEVA)
Synageva BioPharma Corp (NASDAQ:GEVA) Director Barry D. Quart sold 1,375 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $100.00, for a total transaction of $137,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Synageva BioPharma Corp (NASDAQ:GEVA) traded up 0.40% during mid-day trading on Tuesday, hitting $102.13. 181,482 shares of the company’s stock traded hands. Synageva BioPharma Corp has a 1-year low of $41.10 and a 1-year high of $119.42. The stock’s 50-day moving average is $84.78 and its 200-day moving average is $85.2. The company’s market cap is $3.372 billion.
Synageva BioPharma Corp (NASDAQ:GEVA) last issued its quarterly earnings data on Friday, May 2nd. The company reported ($1.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($1.19) by $0.03. Analysts expect that Synageva BioPharma Corp will post $-5.93 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Leerink Swann reiterated a “market perform” rating on shares of Synageva BioPharma Corp in a research note on Thursday, May 15th. They now have a $89.00 price target on the stock, down previously from $101.00. Separately, analysts at Nomura cut their price target on shares of Synageva BioPharma Corp from $144.00 to $140.00 in a research note on Thursday, May 1st. They now have a “buy” rating on the stock. Finally, analysts at Janney Montgomery Scott upgraded shares of Synageva BioPharma Corp from a “neutral” rating to a “buy” rating in a research note on Thursday, May 1st. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Synageva BioPharma Corp currently has a consensus rating of “Buy” and an average price target of $108.29.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.